{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:44:04Z","timestamp":1772005444451,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2014,8,4]],"date-time":"2014-08-04T00:00:00Z","timestamp":1407110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center, NIH","doi-asserted-by":"crossref","award":["D43TW001140"],"award-info":[{"award-number":["D43TW001140"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center, NIH","doi-asserted-by":"crossref","award":["D43TW007393"],"award-info":[{"award-number":["D43TW007393"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIAID, National Institutes of Health, Intramural Research Program"},{"DOI":"10.13039\/100000002","name":"NINDS, National Institutes of Health","doi-asserted-by":"crossref","award":["R01NS054805"],"award-info":[{"award-number":["R01NS054805"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Wellcome Trust","award":["091077"],"award-info":[{"award-number":["091077"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Neurocysticercosis (NCC) is a major cause of seizures and epilepsy in endemic countries. Antiparasitic treatment of brain cysts leads to seizures due to the host's inflammatory reaction, requiring concomitant steroids. We hypothesized that increased steroid dosing will reduce treatment\u2010associated seizures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Open\u2010label randomized trial comparing 6\u00a0mg\/day dexamethasone for 10\u00a0days (conventional) with 8\u00a0mg\/day for 28\u00a0days followed by a 2\u2010week taper (enhanced) in patients with NCC receiving albendazole. Follow\u2010up included active seizure surveillance and brain imaging. Study outcomes were seizure days and patients with seizures, both measured in days 11\u201342. Additional analyses compared days 1\u201310, 11\u201321, 22\u201332, 33\u201342, 43\u201360, and 61\u2013180.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010two individuals were randomized into each study arm; two did not complete follow\u2010up. From days 11 to 42, 59 partial and 6 generalized seizure days occurred in 20 individuals, nonsignificantly fewer in the enhanced arm (12 vs. 49, p\u00a0=\u00a00.114). The numbers of patients with seizures in this period showed similar nonsignificant differences. In the enhanced steroid arm there were significantly fewer days and individuals with seizures during antiparasitic treatment (days 1\u201310: 4 vs. 17, p\u00a0=\u00a00.004, and 1 vs. 10, p\u00a0=\u00a00.003, number needed to treat [NNT] 4.6, relative risk [RR] 0.1013, 95% confidence interval [<jats:styled-content style=\"fixed-case\">CI]<\/jats:styled-content> 0.01\u20130.74) and early after dexamethasone cessation (days 11\u201321: 6 vs. 27, p\u00a0=\u00a00.014, and 4 vs. 12, p\u00a0=\u00a00.021, <jats:styled-content style=\"fixed-case\">NNT<\/jats:styled-content> 4.0, <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content> 0.33, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.12\u20130.92) but not after day 21. There were no significant differences in antiparasitic efficacy or relevant adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance<\/jats:title><jats:p>Increased dexamethasone dosing results in fewer seizures for the first 21\u00a0days during and early after antiparasitic treatment for viable parenchymal NCC but not during the first 11\u201342\u00a0days, which was the primary predetermined time of analysis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/epi.12739","type":"journal-article","created":{"date-parts":[[2014,8,4]],"date-time":"2014-08-04T21:38:55Z","timestamp":1407188335000},"page":"1452-1459","source":"Crossref","is-referenced-by-count":53,"title":["Enhanced steroid dosing reduces seizures during antiparasitic treatment for cysticercosis and early after"],"prefix":"10.1111","volume":"55","author":[{"given":"Hector H.","family":"Garcia","sequence":"first","affiliation":[{"name":"Cysticercosis Unit National Institute of Neurological Sciences Lima Peru"},{"name":"Department of Microbiology School of Sciences Cayetano Heredia Peruvian University Lima Peru"},{"name":"Center for Global Health \u2013 Tumbes Cayetano Heredia Peruvian University Lima Peru"},{"name":"School of Public Health Cayetano Heredia Peruvian University Lima Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isidro","family":"Gonzales","sequence":"additional","affiliation":[{"name":"Cysticercosis Unit National Institute of Neurological Sciences Lima Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres G.","family":"Lescano","sequence":"additional","affiliation":[{"name":"School of Public Health Cayetano Heredia Peruvian University Lima Peru"},{"name":"Department of Parasitology and Public Health Training Program US Naval Medical Research Unit No. 6 (NAMRU\u20106) Lima Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier A.","family":"Bustos","sequence":"additional","affiliation":[{"name":"Center for Global Health \u2013 Tumbes Cayetano Heredia Peruvian University Lima Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Javier","family":"Pretell","sequence":"additional","affiliation":[{"name":"Hospital National Alberto Sabogal ESSALUD Callao Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Saavedra","sequence":"additional","affiliation":[{"name":"Cysticercosis Unit National Institute of Neurological Sciences Lima Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore E.","family":"Nash","sequence":"additional","affiliation":[{"name":"Gastrointestinal Parasites Section Laboratory of Parasitic Diseases NIAID NIH Bethesda Maryland U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Cysticercosis Working Group in Peru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,8,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(05)70194-0"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2011.135"},{"key":"e_1_2_8_4_1","first-page":"27","volume-title":"Cysticercosis of the central nervous system","author":"Escobar A","year":"1983"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198404193101601"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2012.01.060"},{"key":"e_1_2_8_7_1","first-page":"307","article-title":"Cerebrospinal fluid syndrome induced by neurocysticercosis","volume":"19","author":"Spina\u2010Franca A","year":"1961","journal-title":"Arq Neuropsiquiatr"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.11.86"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2012.12.010"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031294"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03121.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.144899"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(93)90095-8"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2003.08003.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2005.09.002"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2006.03.003"},{"key":"e_1_2_8_18_1","first-page":"419","article-title":"Short course of oral prednisolone on disappearance of lesion and seizure recurrence in patients of solitary cysticercal granuloma with single small enhancing CT lesion: an open label randomized prospective study","volume":"55","author":"Kishore D","year":"2007","journal-title":"J Assoc Phys India"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03184.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31827b90a8"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1991.tb04996.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31820202dc"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.12.2315"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.12739","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.12739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:48:34Z","timestamp":1695570514000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.12739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,4]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/epi.12739"],"URL":"https:\/\/doi.org\/10.1111\/epi.12739","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,4]]}}}